In this issue
Putting the rise of STIs in England into contextSubscription
Laura Waters explains the rise of STIs in the UK, the possible reasons behind it and possible solutions, and considers the challenges posed by the current economic climate.
With the NHS working towards the integration of personalised medicine, in particular, aiming for whole-genome sequencing to be standard for specific conditions by 2020, it is important for pharmacists and healthcare professionals to be aware of the principles of pharmacogenomics and its evolving application into clinical practice.
Cardiovascular disease (CVD) is one of the biggest killers in the UK, with associated co-morbidities costing the NHS more than £10bn every year. Community pharmacists are well placed to reduce this costly health burden through the delivery of locally commissioned services that focus on risk factors — hypertension, obesity and smoking. These services, however, must not only deliver positive patient health outcomes but must also be cost-effective.
As one of those whose passions were aroused by testosterone replacement therapy (TRT) in men, I am delighted that Clinical Pharmacist has provided Geoff Hackett with a platform to clarify the current clinical position (Clinical Pharmacist 2017;9:195). Hackett rightly points out that we should have no truck with ...
Promoting oral health in the communitySubscription
Dental caries caused 63,000 children to be admitted to hospital for surgery in 2014. In that year, approximately one-quarter of British five-year-olds suffered with tooth decay and more than one-third of children did not see a dentist
Study investigated the link between non-steroidal anti-inflammatory drugs and raised blood pressure and heart problems in patients who either had, or were at increased risk, of coronary artery disease.
Study suggests that serotonin 2C receptor agonists may be useful in preventing metabolic side effects associated with taking atypical antipsychotics.
A diagnostic test for urinary tract infections, that affect 100 million women annually, could be valuable in the fight against antimicrobial resistance.
A study in the Annals of Internal Medicine suggests that continuing statin treatment beyond the first two years can be beneficial.